title: [Evaluation of the pharmacoeconomic efficacy of prestance in the treatment of hypertensive patients on the basis of the results of the POTENTIAL program].
abstract: OBJECTIVE
  To pharmacoeconomically estimate the use of a fixed-dose combination of perindopril and amlodipine in the treatment of hypertensive patients.
  
  
  METHODS
  A pharmacoeconomic study was conducted on the basis of the Russian postmarketing observational open program POTENTIAL, which included the estimation of direct and indirect costs associated with the addition of a fixed-dose combination of perindopril and amlodipine to conventional therapy for hypertension in patients who had not achieved adequate blood pressure (BP) control. Cost-difference, cost-effectiveness, and budget-impact analyses were carried out.
  
  
  RESULTS
  The addition of prestance to conventional therapy for hypertension can reduce total costs by 5.-5.8 times, direct costs required to achieve 1% of patients with adequate BP control by 20.5-42.1 times, and direct costs to improve a patient's status by one visual analogue scale score by 1.03-2.11 times. Within a 5-year horizon, the administration of prestance can decrease the cost of therapy for high BP and related strokes by 1.39-1.46 times.
  
  
  CONCLUSIONS
  Due its high efficacy, prestance (amlodipine + perindopril) is a pharmacoeconomically preferred alternative only to the conventional therapy for hypertension even if the least costly generics are used, in both the short and medium term.
authors.affiliation: 1I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
authors.forename: I N
authors.initials: IN
authors.lastname: Dyakov
authors.affiliation: 2I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
authors.forename: M G
authors.initials: MG
authors.lastname: Glezer
mesh_terms: D017311:Amlodipine / Q000191:economics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D001794:Blood Pressure; D004338:Drug Combinations; D017850:Economics, Pharmaceutical; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D020913:Perindopril / Q000191:economics / Q000627:therapeutic use; D012426:Russia
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D017311:Amlodipine; D020913:Perindopril